Newsroom

Truveris experts explore the expanding GLP-1 market, biosimilars, the 2026 drug pipeline, and emerging policy changes that could reshape PBM dynamics.

Meet the newest members of Truveris’ expanded clinical team who will further strengthen our ability to provide pharmacy benefits advisory support.

Truveris experts discuss 100% pharma tariffs, Most Favored Nation pricing, and TrumpRx, with key considerations for plans.

Truveris’ press release on collaboration with Mark Cuban Cost Plus Drugs.

Truveris has secured $15 Million in Series E funding.

Truveris has elevated three industry experts to the c-suite team to further the company mission.

Benefit Advisors Network (BAN), an international network of employee benefit brokers and consulting firms has developed a strategic partnership with Truveris.

On May 17, 2022, the U.S. District Court for DC ruled against the “accumulator adjustment rule.” What impact will this have on pharma?

The State of Minnesota has selected Truveris as its exclusive pharmacy benefits procurement and oversight partner for 52,000 employees.

Truveris announced today that Nanette Oddo, formerly Truveris’ Chief Strategy Officer, has been named President and Chief Executive Officer.

Several states have passed copay accumulator laws that prohibit the use of copay accumulator adjustment programs. How does this affect your organization?

The Truveris leadership team has expanded to include six seasoned healthcare and technology veterans.

In October of 2017, Anthem Inc. announced its launching of IngenioRx, an in-house pharmacy benefits manager (PBM).